AccuraGen Highlights New Developments in MRD Detection with AccuScan Whole-Genome Sequencing Solution

AccuraGen, a leading precision oncology firm, has taken a significant step toward transforming cancer diagnostics with its cutting-edge AccuScan assay. This whole-genome sequencing (WGS) liquid biopsy test is designed to detect minimal residual disease (MRD) with high sensitivity, specificity, and rapid turnaround, addressing a critical need in post-treatment cancer monitoring.

The company’s breakthrough technology was recently highlighted in a GenomeWeb interview, where AccuraGen shared the key benefits of the AccuScan assay, which is tumor-informed but does not require custom reagents. The test analyzes circulating tumor DNA (ctDNA) from plasma samples using a highly efficient workflow that includes intramolecular ligation and rolling circle amplification. This innovative method enables AccuScan to deliver accurate results even from samples with low DNA input, making it an ideal solution for early detection of cancer recurrence.

In a peer-reviewed study published in EMBO Molecular Medicine, AccuraGen demonstrated the utility of AccuScan across multiple cancer types, including colorectal cancer (CRC), esophageal squamous cell carcinoma (ESCC), and melanoma. The assay achieved 90% sensitivity and 100% specificity in CRC patients, positioning AccuScan as a highly reliable tool for detecting MRD post-surgery. The study also confirmed that the technology’s genome-wide error correction can detect ctDNA at levels as low as parts-per-million, marking a significant advancement in precision oncology.

“Our goal is to bring next-generation MRD testing to clinicians and researchers, and the AccuScan assay is poised to offer unparalleled accuracy and flexibility,” said Li Weng, Senior Vice President of R&D at AccuraGen. “With its fast turnaround time and ability to work with low-input DNA samples, AccuScan provides a new standard in liquid biopsy testing.”

AccuraGen plans to offer AccuScan as a research-use-only service in 2025, with a clinical rollout expected by 2026. The company is also exploring strategic partnerships with clinical labs and pharmaceutical companies to accelerate market adoption.

https://www.genomeweb.com/liquid-biopsy/accuragen-aims-mrd-detection-market-tumor-informed-wgs-liquid-biopsy-assay

‍